Aripiprazole for the treatment of methamphetamine dependence: a randomized, double‐blind, placebo‐controlled trial
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Aims: To test aripiprazole for efficacy in decreasing use in methamphetamine‐dependent adults, compared to placebo. Design: Participants were randomized to receive 12 weeks of aripiprazole or placebo, with a 3‐month follow‐up and a platform of weekly 30‐minute substance abuse counseling. Setting: The trial was conducted from J anuary 2009 to M arch 2012 at the San Francisco Department of Public Health. Participants: Ninety actively using, methamphetamine‐dependent, sexually active adults were recruited from community venues. Measurements: The primary outcome was regression estimated reductions in weekly methamphetamine‐positive urines. Secondary outcomes were study medication adherence [by self‐report and medication event monitoring systems (MEMS)], sexual risk behavior and abstinence from methamphetamine. Findings: Participant mean age was 38.7 years, 87.8% were male, 50.0% white, 18.9% African American, and 16.7% Latino. Eighty‐three per cent of follow‐up visits and final visits were completed. By intent‐to‐treat, participants assigned to aripiprazole had similar reductions in methamphetamine‐positive urines as participants assigned to placebo [risk ratio (RR) 0.88, 95% confidence interval (CI): 0.66–1.19,P = 0.41]. Urine positivity declined from 73% (33 of 45 participants) to 45% (18 of 40) in the placebo arm and from 77% (34 of 44) to 44% (20 of 35) in the aripiprazole arm. Adherence by MEMS and self‐report was 42 and 74%, respectively, with no significant difference between arms (MEMS P = 0.31; self‐report P = 0.17). Most sexual risk behaviors declined similarly among participants in both arms (all P > 0.05). There were no serious adverse events related to study drug, although participants randomized to aripiprazole reported more akathisia, fatigue and drowsiness (P < 0.05). Conclusion: Compared with placebo, aripiprazole did not reduce methamphetamine use significantly among actively using, dependent adults.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Addiction: Beyond dopamine reward circuitry
Volkow, N. D., Wang, G.-J., Fowler, J. S., Tomasi, D., & Telang, F. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010654108 · Cited by 959
Tonstad, S. (2006) · JAMA · doi:10.1001/jama.296.1.64 · Cited by 660
Pharmacological approaches to methamphetamine dependence: a focused review
Karila, L., Weinstein, A., Aubin, H., Benyamina, A., Reynaud, M., & Batki, S. L. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03639.x · Cited by 242 · cited 2×
“(5)Despite multiple adjustments for possible confounders, our efficacy estimates from the intention-to-treat analysis were essentially unchanged.”
BackgroundMethodMirtazapine to Reduce Methamphetamine Use: A Randomized Controlled Trial
Colfax, G. N. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.124 · Cited by 175 · cited 1×
“Adherence was limited, yet similar or superior to many trials in this population(27, 39, 40)and probably within range of real-world expectations.”
ResultSelf-citationAmphetamine-group substances and HIV
Colfax, G., Santos, G.-M., Chu, P., Vittinghoff, E., Pluddemann, A., Kumar, S., & Hart, C. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60753-2 · Cited by 167 · cited 3×
“(2)Methamphetamine is associated with substantial morbidity and mortality, (3)decreased inhibitions, increased perceptions of invulnerability, high-risk sexual behaviors for HIV transmission, and incidence of HIV and other sexually-transmitted infections.(3, 4)In contrast to therapies for opioid, nicotine, and alcohol…”
BackgroundSelf-citationBrown, E. S., Jeffress, J., Liggin, J. D. M., Garza, M., & Beard, L. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0613 · Cited by 118 · cited 1×
“(20– 24)Finally, pilot clinical studies demonstrated reduced use or craving for other psychostimulants.(25, 26)”
BackgroundA low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine
Stoops, W. W., Lile, J. A., Glaser, P. E. A., & Rush, C. R. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.02.004 · Cited by 57
Cited by
Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review
Siefried, K. J., Acheson, L. S., Lintzeris, N., & Ezard, N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00711-x · Cited by 194
Pharmacotherapy for methamphetamine/amphetamine use disorder—a systematic review and meta‐analysis
Chan, B., Freeman, M., Kondo, K., Ayers, C., Montgomery, J., Paynter, R., & Kansagara, D. (2019) · Addiction · doi:10.1111/add.14755 · Cited by 160
Randomized controlled trial of a positive affect intervention for methamphetamine users
Carrico, A. W., Gόmez, W., Jain, J., Shoptaw, S., Discepola, M. V., Olem, D., Lagana-Jackson, J., Andrews, R., Neilands, T. B., Dilworth, S. E., et al. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.07.029 · Cited by 56
Härtel-Petri, R., Krampe-Scheidler, A., Braunwarth, W.-D., Havemann-Reinecke, U., Jeschke, P., Looser, W., Mühlig, S., Schäfer, I., Scherbaum, N., Bothe, L., et al. (2017) · Pharmacopsychiatry · doi:10.1055/s-0043-105500 · Cited by 39
Srisurapanont, M., Likhitsathian, S., Suttajit, S., Maneeton, N., Maneeton, B., Oon‐arom, A., & Suradom, C. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108467 · Cited by 26
Metadata
- Authors
- Coffin, P. O., Santos, G., Das, M., Santos, D. M., Huffaker, S., Matheson, T., Gasper, J., Vittinghoff, E., & Colfax, G. N.
- Venue
- Addiction
- Publisher
- Wiley
- Published
- 2013-01-03
- Volume
- 108
- Issue
- 4
- Pages
- 751-761
- ISSN
- 0965-2140 (ISSN-L)
- 1360-0443
- OpenAlex
- W1962253127
- Cited by
- 67
- References
- 9
- FWCI
- 3.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aripiprazole for the treatment of methamphetamine dependence: a randomized, double‐blind, placebo‐controlled trial. https://app.cochat.ai/papers/10.1111/add.12073
- The paper
- Coffin, P. O., Santos, G., Das, M., Santos, D. M., Huffaker, S., Matheson, T., Gasper, J., Vittinghoff, E., & Colfax, G. N. (2013). Aripiprazole for the treatment of methamphetamine dependence: a randomized, double‐blind, placebo‐controlled trial. Addiction. https://doi.org/10.1111/add.12073
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.